ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and index-based criteria previously used and the revisions made in 2022.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis.‘ (Abstract number: 1414) was presented at the ACR Convergence, November 10–14, 2022.
- What were the limitations of the Boolean and index-based criteria used by the ACR and EULAR to define remission in RA? (0:16)
- What are the revisions of the Boolean remission criteria? (2:41)
Disclosures: Paul Studenic has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Peter Taylor, EULAR 2023: Current perspectives on the selectivity and safety of JAK inhibitors to target the pathophysiology of rheumatoid arthritis
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]
Jérôme Avouac, EULAR 2023: Effects of B cell depletion by CD19-targeted CAR-T cells in a murine model of systemic sclerosis
touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on the potential of CD19-targeted CAR-T cell transfer for systemic sclerosis. The abstract ‘Effects of B cell depletion by […]
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!